Activation of the MEK/extracellular regulated kinase pathway through KRAS mutations as an escape mechanism and efficacy of the combined EGFR and MEK inhibition was reported previously.17,26,27 Thus, taken together, treatment of EGFR-mutant NSCLC with TKIs targeting EGFR as well as MET and MEK may delay the development of AR and prevent IR in selected patients. Here, KRAS is linked to non-small cell lung carcinoma.